Human monocyte activation by biologic and biodegradable meshes in vitro
- 360 Downloads
Inflammation and wound healing play critical roles in the integration of biologic and biodegradable meshes (BMs) at hernia repair sites. Monocytes/macrophages (M/MØs) are key cells controlling inflammation and wound healing. These cells release inflammatory cytokines and growth factors such as interleukin (IL)-1β, IL-6, IL-8, and vascular endothelial growth factor (VEGF) upon activation. Although BMs have been increasingly used in hernia repairs worldwide, to date, investigations of inflammatory responses to various BMs have been limited.
Mesh samples of three acellular human dermis-derived biologic meshes (AlloDerm, AlloMax, FlexHD) and one biodegradable synthetic mesh (Bio-A) were placed in 96-well plates. Human peripheral blood mononuclear cells (PBMCs) were isolated from six healthy subjects, added to each well, and incubated for 7 days. Culture supernatants were assayed for IL-1β, IL-6, IL-8, and VEGF levels using a multiplex bead-base immunoassay system (Bio-Plex).
All four meshes induced cytokine expression from activated M/MØs to varying degrees in vitro. FlexHD induced significantly more IL-1β (2,591 pg/ml) than AlloMax (517 pg/ml), AlloDerm (48 pg/ml), or Bio-A (28 pg/ml) (p < 0.001). AlloMax stimulated a significantly greater quantity of IL-6 (38,343 pg/ml) than FlexHD (19,317 pg/ml), Bio-A (191 pg/ml), or AlloDerm (103 pg/ml) (p < 0.05). Interleukin-8 and VEGF displayed trends similar to that of IL-6. There were no significant differences in cytokine production between AlloDerm and Bio-A.
This study demonstrated that human macrophages are activated by human dermis-derived biologic and biodegradable meshes in vitro. A wide range of cytokine and growth factor induction was seen among the different mesh products. These differences in M/MØ activation may be related to the proprietary processing technologies of the studied meshes. The study results raise the possibility that these differences in M/MØ activation could indicate varying intensities of inflammation that control integration of different biologic meshes at the sites of hernia repair.
KeywordsBiologic mesh Cytokine Growth factor Human dermis Monocyte/macrophage Mononuclear cells
This study was funded in part by institutional support from the University of Connecticut Health Center.
- 1.Gray SH, Hawn MT, Itani KM (2008) Surgical progress in inguinal and ventral incisional hernia repair. Surg Clin North Am 88:17–26, viiGoogle Scholar
- 2.Rutkow IM (2003) Demographic and socioeconomic aspects of hernia repair in the United States in 2003. Surg Clin North Am 83:1045–1051, v–viGoogle Scholar
- 4.Bachman S, Ramshaw B (2008) Prosthetic material in ventral hernia repair: how do I choose? Surg Clin North Am 88:101–112, ixGoogle Scholar
- 7.Milburn ML, Holton LH, Chung TL, Li EN, Bochicchio GV, Goldberg NH, Silverman RP (2008) Acellular dermal matrix compared with synthetic implant material for repair of ventral hernia in the setting of perioperative Staphylococcus aureus implant contamination: a rabbit model. Surg Infect Larchmt 9:433–442CrossRefPubMedGoogle Scholar
- 19.Butler CE (2006) The role of bioprosthetics in abdominal wall reconstruction. Clin Plast Surg 33:199–211, v–viGoogle Scholar
- 23.Kaback LA, Smith TJ (1999) Expression of hyaluronan synthase messenger ribonucleic acids and their induction by interleukin-1 beta in human orbital fibroblasts: potential insight into the molecular pathogenesis of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 84:4079–4084CrossRefPubMedGoogle Scholar
- 25.Yamada Y, Itano N, Hata K, Ueda M, Kimata K (2004) Differential regulation by IL-1 beta and EGF of expression of three different hyaluronan synthases in oral mucosal epithelial cells and fibroblasts and dermal fibroblasts: quantitative analysis using real-time RT-PCR. J Invest Dermatol 122:631–639CrossRefPubMedGoogle Scholar
- 34.Yoo SA, Bae DG, Ryoo JW, Kim HR, Park GS, Cho CS, Chae CB, Kim WU (2005) Arginine-rich antivascular endothelial growth factor (anti-VEGF) hexapeptide inhibits collagen-induced arthritis and VEGF-stimulated productions of TNF-alpha and IL-6 by human monocytes. J Immunol 174:5846–5855PubMedGoogle Scholar